Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Smith, J. S.
Right arrow Articles by Jenkins, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Smith, J. S.
Right arrow Articles by Jenkins, R. B.
Journal of Clinical Oncology, Vol 18, Issue 3 (February), 2000: 636
© 2000 American Society for Clinical Oncology

Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas

By Justin S. Smith, Arie Perry, Thomas J. Borell, Hyun K. Lee, Judith O’Fallon, Sandra M. Hosek, David Kimmel, Allan Yates, Peter C. Burger, Bernd W. Scheithauer, Robert B. Jenkins

From the Division of Laboratory Genetics, Division of Anatomic Pathology, Department of Neurology, and Section of Biostatistics, Mayo Clinic and Foundation, Rochester, MN; Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD; Division of Neuropathology, Ohio State University, Columbus, OH; and Washington University School of Medicine, St Louis, MO.

Address reprint requests to Robert B. Jenkins, MD, PhD, Department of Cytogenetics, Mayo Clinic, 200 First St, Southwest, Rochester, MN 55905; email rjenkins{at}mayo.edu

PURPOSE: A recent report suggests that alterations of chromosome arms 1p and 19q are associated with chemotherapeutic response and overall survival in anaplastic oligodendroglioma patients treated with procarbazine, lomustine, and vincristine chemotherapy. We set out to further clarify the diagnostic and prognostic implications of these alterations in a broader set of diffuse gliomas, including astrocytic neoplasms and low-grade oligodendrogliomas.

PATIENTS AND METHODS: Fluorescence in situ hybridization (FISH) signals from DNA probes mapping to 1p and 19q common deletion regions were enumerated in 162 diffuse gliomas (79 astrocytomas, 52 oligodendrogliomas, and 31 mixed oligoastrocytomas), collected as part of an ongoing prospective investigation of CNS tumors.

RESULTS: The oligodendroglial phenotype was highly associated with loss of 1p (P = .0002), loss of 19q (P < .0001), and combined loss of 1p and 19q (P < .0001). Combined loss of 1p and 19q was identified as a univariate predictor of prolonged overall survival among patients with pure oligodendroglioma (log-rank, P = .03) and remained a significant predictor after adjusting for the effects of patient age and tumor grade (P < .01). This favorable association was not evident in patients with astrocytoma or mixed oligoastrocytoma.

CONCLUSION: Combined loss of 1p and 19q is a statistically significant predictor of prolonged survival in patients with pure oligodendroglioma, independent of tumor grade. Given the lack of this association in patients with astrocytic neoplasms and the previously demonstrated chemosensitivity of oligodendrogliomas, a combined approach of histologic and genotypic assessment could potentially improve existing strategies for patient stratification and management.

The first two authors contributed equally to this study.




This article has been cited by other articles:


Home page
 Am. J. Neuroradiol.Home page
K.E. Emblem, D. Scheie, P. Due-Tonnessen, B. Nedregaard, T. Nome, J.K. Hald, K. Beiske, T.R. Meling, and A. Bjornerud
Histogram Analysis of MR Imaging-Derived Cerebral Blood Volume Maps: Combined Glioma Grading and Identification of Low-Grade Oligodendroglial Subtypes
AJNR Am. J. Neuroradiol., October 1, 2008; 29(9): 1664 - 1670.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. Brown, M. Zlatescu, A. Sijben, G. Roldan, J. Easaw, P. Forsyth, I. Parney, R. Sevick, E. Yan, D. Demetrick, et al.
The Use of Magnetic Resonance Imaging to Noninvasively Detect Genetic Signatures in Oligodendroglioma
Clin. Cancer Res., April 15, 2008; 14(8): 2357 - 2362.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. E. Wohlfahrt, B. C. Beard, A. Lieber, and H.-P. Kiem
A Capsid-Modified, Conditionally Replicating Oncolytic Adenovirus Vector Expressing TRAIL Leads to Enhanced Cancer Cell Killing in Human Glioblastoma Models
Cancer Res., September 15, 2007; 67(18): 8783 - 8790.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
L. E. Abrey, D. N. Louis, N. Paleologos, A. B. Lassman, J. J. Raizer, W. Mason, J. Finlay, D. R. MacDonald, L. M. DeAngelis, J. G. Cairncross, et al.
Survey of treatment recommendations for anaplastic oligodendroglioma
Neuro-oncol, July 1, 2007; 9(3): 314 - 318.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Hong, K. S. Moorefield, P. Jun, K. D. Aldape, S. Kharbanda, H. S. Phillips, and J. F. Costello
Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth
PNAS, June 26, 2007; 104(26): 10974 - 10979.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Lavon, D. Zrihan, B. Zelikovitch, Y. Fellig, D. Fuchs, D. Soffer, and T. Siegal
Longitudinal Assessment of Genetic and Epigenetic Markers in Oligodendrogliomas
Clin. Cancer Res., March 1, 2007; 13(5): 1429 - 1437.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. R. Miller, C. P. Dunham, B. W. Scheithauer, and A. Perry
Significance of Necrosis in Grading of Oligodendroglial Neoplasms: A Clinicopathologic and Genetic Study of Newly Diagnosed High-Grade Gliomas
J. Clin. Oncol., December 1, 2006; 24(34): 5419 - 5426.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
F. Okahara, K. Itoh, A. Nakagawara, M. Murakami, Y. Kanaho, and T. Maehama
Critical Role of PICT-1, a Tumor Suppressor Candidate, in Phosphatidylinositol 3,4,5-Trisphosphate Signals and Tumorigenic Transformation
Mol. Biol. Cell, November 1, 2006; 17(11): 4888 - 4895.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. B. Jenkins, H. Blair, K. V. Ballman, C. Giannini, R. M. Arusell, M. Law, H. Flynn, S. Passe, S. Felten, P. D. Brown, et al.
A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with Oligodendroglioma.
Cancer Res., October 15, 2006; 66(20): 9852 - 9861.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, L. Bonaldi, R. Bertorelle, M. Gardiman, C. Ghimenton, P. Iuzzolino, et al.
Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study
J. Clin. Oncol., October 10, 2006; 24(29): 4746 - 4753.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Mariani, G. Deiana, E. Vassella, A.-R. Fathi, C. Murtin, M. Arnold, I. Vajtai, J. Weis, P. Siegenthaler, M. Schobesberger, et al.
Loss of Heterozygosity 1p36 and 19q13 Is a Prognostic Factor for Overall Survival in Patients With Diffuse WHO Grade 2 Gliomas Treated Without Chemotherapy
J. Clin. Oncol., October 10, 2006; 24(29): 4758 - 4763.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
J. Jeuken, S. Cornelissen, S. Boots-Sprenger, S. Gijsen, and P. Wesseling
Multiplex Ligation-Dependent Probe Amplification: A Diagnostic Tool for Simultaneous Identification of Different Genetic Markers in Glial Tumors
J. Mol. Diagn., September 1, 2006; 8(4): 433 - 443.
[Abstract] [Full Text] [PDF]

Home page
 BiostatisticsHome page
D. A. Engler, G. Mohapatra, D. N. Louis, and R. A. Betensky
A pseudolikelihood approach for simultaneous analysis of array comparative genomic hybridizations
Biostat., July 1, 2006; 7(3): 399 - 421.
[Abstract] [Full Text] [PDF]

Home page
 BrainHome page
M. D. Jenkinson, D. G. du Plessis, T. S. Smith, K. A. Joyce, P. C. Warnke, and C. Walker
Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features
Brain, July 1, 2006; 129(7): 1884 - 1891.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperierre, et al.
Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402
J. Clin. Oncol., June 20, 2006; 24(18): 2707 - 2714.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. van den Bent, A. F. Carpentier, A. A. Brandes, M. Sanson, M. J.B. Taphoorn, H. J.J.A. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, et al.
Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial
J. Clin. Oncol., June 20, 2006; 24(18): 2715 - 2722.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Walker, B. Haylock, D. Husband, K. A. Joyce, D. Fildes, M. D. Jenkinson, T. Smith, J. Broome, D. G. du Plessis, and P. C. Warnke
Clinical use of genotype to predict chemosensitivity in oligodendroglial tumors
Neurology, June 13, 2006; 66(11): 1661 - 1667.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. T. Grier and T. Batchelor
Low-grade gliomas in adults.
Oncologist, June 1, 2006; 11(6): 681 - 693.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
G. Mohapatra, R. A. Betensky, E. R. Miller, B. Carey, L. D. Gaumont, D. A. Engler, and D. N. Louis
Glioma Test Array for Use with Formalin-Fixed, Paraffin-Embedded Tissue: Array Comparative Genomic Hybridization Correlates with Loss of Heterozygosity and Fluorescence in Situ Hybridization
J. Mol. Diagn., May 1, 2006; 8(2): 268 - 276.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
L. E. Abrey, B. H. Childs, N. Paleologos, L. Kaminer, S. Rosenfeld, D. Salzman, J. L. Finlay, S. Gardner, K. Peterson, W. Hu, et al.
High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up
Neuro-oncol, April 1, 2006; 8(2): 183 - 188.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. F. Lang and M. R. Gilbert
Diffusely Infiltrative Low-Grade Gliomas in Adults
J. Clin. Oncol., March 10, 2006; 24(8): 1236 - 1245.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
K. A. Jaeckle, K. V. Ballman, R. D. Rao, R. B. Jenkins, and J. C. Buckner
Current Strategies in Treatment of Oligodendroglioma: Evolution of Molecular Signatures of Response
J. Clin. Oncol., March 10, 2006; 24(8): 1246 - 1252.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
N. Hata, K. Yoshimoto, N. Yokoyama, M. Mizoguchi, T. Shono, Y. Guan, T. Tahira, Y. Kukita, K. Higasa, S. Nagata, et al.
Allelic Losses of Chromosome 10 in Glioma Tissues Detected by Quantitative Single-Strand Conformation Polymorphism Analysis
Clin. Chem., March 1, 2006; 52(3): 370 - 378.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
P. J. French, S. M.A. Swagemakers, J. H.A. Nagel, M. C.M. Kouwenhoven, E. Brouwer, P. van der Spek, T. M. Luider, J. M. Kros, M. J. van den Bent, and P. A. Sillevis Smitt
Gene Expression Profiles Associated with Treatment Response in Oligodendrogliomas
Cancer Res., December 15, 2005; 65(24): 11335 - 11344.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. W. Song, G. N. Fuller, H. Zheng, and W. Zhang
Inactivation of the Invasion Inhibitory Gene IIp45 by Alternative Splicing in Gliomas
Cancer Res., May 1, 2005; 65(9): 3562 - 3567.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Hong, A. Maunakea, P. Jun, A. W. Bollen, J. G. Hodgson, D. D. Goldenberg, W. A. Weiss, and J. F. Costello
Shared Epigenetic Mechanisms in Human and Mouse Gliomas Inactivate Expression of the Growth Suppressor SLC5A8
Cancer Res., May 1, 2005; 65(9): 3617 - 3623.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
P. G. Fisher and P. A. Buffler
Malignant Gliomas in 2005: Where to GO From Here?
JAMA, February 2, 2005; 293(5): 615 - 617.
[Full Text] [PDF]

Home page
 Am. J. Neuroradiol.Home page
S. Cha, T. Tihan, F. Crawford, N. J. Fischbein, S. Chang, A. Bollen, S. J. Nelson, M. Prados, M. S. Berger, and W. P. Dillon
Differentiation of Low-Grade Oligodendrogliomas from Low-Grade Astrocytomas by Using Quantitative Blood-Volume Measurements Derived from Dynamic Susceptibility Contrast-Enhanced MR Imaging
AJNR Am. J. Neuroradiol., February 1, 2005; 26(2): 266 - 273.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
A. D. Voloschin, D. N. Louis, G. R. Cosgrove, and T. T. Batchelor
Neoadjuvant temozolomide followed by complete resection of a 1p- and 19q-deleted anaplastic oligoastrocytoma: Case study
Neuro-oncol, January 1, 2005; 7(1): 97 - 100.
[Abstract] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Korshunov, R. Sycheva, and A. Golanov
Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells: The Utility of Fluorescence In situ Hybridization
Clin. Cancer Res., December 1, 2004; 10(23): 7820 - 7826.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. G. Cairncross
Imaging Molecular Signatures in Oligodendroglioma: Commentary on Walker et al., pages 7182-7191
Clin. Cancer Res., November 1, 2004; 10(21): 7109 - 7111.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Walker, D. G. du Plessis, D. Fildes, B. Haylock, D. Husband, M. D. Jenkinson, K. A. Joyce, J. Broome, K. Kopitski, J. Prosser, et al.
Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component
Clin. Cancer Res., November 1, 2004; 10(21): 7182 - 7191.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
E. N. Eskandar, J. S. Loeffler, A. M. O'Neill, G. J. Hunter, and D. N. Louis
Case 33-2004 - A 34-Year-Old Man with a Seizure and a Frontal-Lobe Brain Lesion
N. Engl. J. Med., October 28, 2004; 351(18): 1875 - 1882.
[Full Text] [PDF]

Home page
 JCOHome page
K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, et al.
Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions
J. Clin. Oncol., August 1, 2004; 22(15): 3133 - 3138.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
R. N. Wiltshire, J. E. Herndon II, A. Lloyd, H. S. Friedman, D. D. Bigner, S. H. Bigner, and R. E. McLendon
Comparative Genomic Hybridization Analysis of Astrocytomas: Prognostic and Diagnostic Implications
J. Mol. Diagn., August 1, 2004; 6(3): 166 - 179.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
P. Leuraud, L. Taillandier, J. Medioni, L. Aguirre-Cruz, E. Criniere, Y. Marie, M. Kujas, J.-L. Golmard, A. Duprez, J.-Y. Delattre, et al.
Distinct Responses of Xenografted Gliomas to Different Alkylating Agents Are Related to Histology and Genetic Alterations
Cancer Res., July 1, 2004; 64(13): 4648 - 4653.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. F. Megyesi, E. Kachur, D. H. Lee, M. C. Zlatescu, R. A. Betensky, P. A. Forsyth, Y. Okada, H. Sasaki, M. Mizoguchi, D. N. Louis, et al.
Imaging Correlates of Molecular Signatures in Oligodendrogliomas
Clin. Cancer Res., July 1, 2004; 10(13): 4303 - 4306.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
C. Lebrun, D. Fontaine, A. Ramaioli, F. Vandenbos, S. Chanalet, M. Lonjon, J. F. Michiels, V. Bourg, P. Paquis, M. Chatel, et al.
Long-term outcome of oligodendrogliomas
Neurology, May 25, 2004; 62(10): 1783 - 1787.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Chakravarti, G. Zhai, Y. Suzuki, S. Sarkesh, P. M. Black, A. Muzikansky, and J. S. Loeffler
The Prognostic Significance of Phosphatidylinositol 3-Kinase Pathway Activation in Human Gliomas
J. Clin. Oncol., May 15, 2004; 22(10): 1926 - 1933.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
D. J. Brat, W. F. Seiferheld, A. Perry, E. H. Hammond, K. J. Murray, A. R. Schulsinger, M. P. Mehta, and W. J. Curran
Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials
Neuro-oncol, April 1, 2004; 6(2): 96 - 103.
[Abstract] [PDF]

Home page
 Neuro OncolHome page
D. A. Reardon, J. A. Quinn, J. N. Rich, S. Gururangan, J. Vredenburgh, J. H. Sampson, J. M. Provenzale, A. Walker, M. Badruddoja, S. Tourt-Uhlig, et al.
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
Neuro-oncol, April 1, 2004; 6(2): 134 - 144.
[Abstract] [PDF]

Home page
 RadioGraphicsHome page
D. K. Naugle, T. D. Duncan, and G. P. Grice
Oligoastrocytoma
RadioGraphics, March 1, 2004; 24(2): 598 - 600.
[Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
M. Wang, K. M. Murphy, P. Kulesza, K. J. Hatanpaa, A. Olivi, A. Tufaro, Y. Erozan, W. H. Westra, P. C. Burger, and K. D. Berg
Molecular Diagnosis of Metastasizing Oligodendroglioma: A Case Report
J. Mol. Diagn., February 1, 2004; 6(1): 52 - 57.
[Abstract] [Full Text]

Home page
 Ann OncolHome page
A. A. Brandes, U. Basso, F. Vastola, A. Tosoni, L. M. Pasetto, A. Jirillo, S. Lonardi, M. K. Paris, H. Koussis, S. Monfardini, et al.
Carboplatin and teniposide as third-line chemotherapy in patients with recurrent oligodendroglioma or oligoastrocytoma: a phase II study
Ann. Onc., December 1, 2003; 14(12): 1727 - 1731.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Hong, A. W. Bollen, and J. F. Costello
The Contribution of Genetic and Epigenetic Mechanisms to Gene Silencing in Oligodendrogliomas
Cancer Res., November 15, 2003; 63(22): 7600 - 7605.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. Walker, D. G. du Plessis, K. A. Joyce, Y. Machell, J. Thomson-Hehir, S. A. Al Haddad, J. C. Broome, and P. C. Warnke
Phenotype versus Genotype in Gliomas Displaying Inter- or Intratumoral Histological Heterogeneity
Clin. Cancer Res., October 15, 2003; 9(13): 4841 - 4851.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
A. Perry
Pathology of low-grade gliomas: An update of emerging concepts
Neuro-oncol, July 1, 2003; 5(3): 168 - 178.
[Abstract] [PDF]

Home page
 Neuro OncolHome page
M. van den Bent, O.-L. Chinot, and J. G. Cairncross
Recent developments in the molecular characterization and treatment of oligodendroglial tumors
Neuro-oncol, April 1, 2003; 5(2): 128 - 138.
[Abstract] [PDF]

Home page
 Cancer Res.Home page
W. A. Weiss, M. J. Burns, C. Hackett, K. Aldape, J. R. Hill, H. Kuriyama, N. Kuriyama, N. Milshteyn, T. Roberts, M. F. Wendland, et al.
Genetic Determinants of Malignancy in a Mouse Model for Oligodendroglioma
Cancer Res., April 1, 2003; 63(7): 1589 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. C. Buckner, D. Gesme Jr, J. R. O'Fallon, J. E. Hammack, S. Stafford, P. D. Brown, R. Hawkins, B. W. Scheithauer, B. J. Erickson, R. Levitt, et al.
Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities
J. Clin. Oncol., January 15, 2003; 21(2): 251 - 255.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
E. C. Burton, K. R. Lamborn, B. G. Feuerstein, M. Prados, J. Scott, P. Forsyth, S. Passe, R. B. Jenkins, and K. D. Aldape
Genetic Aberrations Defined by Comparative Genomic Hybridization Distinguish Long-Term from Typical Survivors of Glioblastoma
Cancer Res., November 1, 2002; 62(21): 6205 - 6210.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Del Valle, S. Enam, C. Lara, C. Ortiz-Hidalgo, C. D. Katsetos, and K. Khalili
Detection of JC Polyomavirus DNA Sequences and Cellular Localization of T-Antigen and Agnoprotein in Oligodendrogliomas
Clin. Cancer Res., November 1, 2002; 8(11): 3332 - 3340.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. Hartmann, L. Johnk, G. Kitange, Y. Wu, L. K. Ashworth, R. B. Jenkins, and D. N. Louis
Transcript Map of the 3.7-Mb D19S112-D19S246 Candidate Tumor Suppressor Region on the Long Arm of Chromosome 19
Cancer Res., July 15, 2002; 62(14): 4100 - 4108.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
W. Mueller, C. Hartmann, A. Hoffmann, W. Lanksch, J. Kiwit, J. Tonn, J. Veelken, J. Schramm, M. Weller, O. D. Wiestler, et al.
Genetic Signature of Oligoastrocytomas Correlates with Tumor Location and Denotes Distinct Molecular Subsets
Am. J. Pathol., July 1, 2002; 161(1): 313 - 319.
[Abstract] [Full Text] [PDF]